Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

REASURE: The Effect of Rimonabant on HbA1c in Overweight or Obese Patients With Type 2 Diabetes Not Adequately Controlled on 2 Oral Antidiabetic Agents.

Trial Profile

REASURE: The Effect of Rimonabant on HbA1c in Overweight or Obese Patients With Type 2 Diabetes Not Adequately Controlled on 2 Oral Antidiabetic Agents.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 09 Dec 2010

At a glance

  • Drugs Rimonabant (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms REASSURE
  • Sponsors Sanofi
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 05 Nov 2008 Sanofi-aventis have reported in a media release that development of rimonabant has been discontinued.
    • 05 Nov 2008 Status changed from recruiting to discontinued, as reported by sanofi-aventis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top